This Small Business Technology Transfer Research (STTR) Phase I project proposes to use high pressures for disaggregation and proper refolding of aggregated proteins in commercial IVIg (immunoglobins for intravenous administration) formulations.
The commercial application of this project will be in improved quality of therapeutic proteins for intravenous administration. Increased process yields will lower patient costs for IVIg therapies, and IVIg formulations with dramatically diminished aggregate content will lower side effects and reduce the risk of severe complications.
